Guobang Pharma Ltd
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives.… Read more
Guobang Pharma Ltd (605507) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.30 Billion CNY
Based on the latest financial reports, Guobang Pharma Ltd (605507) has total liabilities worth CN¥2.30 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guobang Pharma Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Guobang Pharma Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Guobang Pharma Ltd Competitors by Total Liabilities
The table below lists competitors of Guobang Pharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nippon Light Metal Holdings Company Ltd
F:N9L
|
Germany | €293.83 Billion |
|
Great Wall Enterprise Co Ltd
TW:1210
|
Taiwan | NT$37.28 Billion |
|
Hanwha Corp Preferred
KO:00088K
|
Korea | ₩237.85 Trillion |
|
China Security & Fire Co Ltd Class A
SHG:600654
|
China | CN¥1.93 Billion |
|
Hanwha Life
KO:088350
|
Korea | ₩153.39 Trillion |
|
Zibo Qixiang Tengda Chemical Co Ltd
SHE:002408
|
China | CN¥13.08 Billion |
|
Bank Handlowy w Warszawie SA
WAR:BHW
|
Poland | zł70.18 Billion |
|
Fortrea Holdings Inc.
NASDAQ:FTRE
|
USA | $2.16 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Guobang Pharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guobang Pharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guobang Pharma Ltd (2017–2024)
The table below shows the annual total liabilities of Guobang Pharma Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.73 Billion | -6.70% |
| 2023-12-31 | CN¥2.92 Billion | +54.85% |
| 2022-12-31 | CN¥1.89 Billion | +61.78% |
| 2021-12-31 | CN¥1.17 Billion | -47.75% |
| 2020-12-31 | CN¥2.23 Billion | +4.24% |
| 2019-12-31 | CN¥2.14 Billion | +20.79% |
| 2018-12-31 | CN¥1.77 Billion | -2.33% |
| 2017-12-31 | CN¥1.82 Billion | -- |